An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E Mutant Colorectal Cancer

  • Strickland, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/67003/PMCC
NMA SSA Reference Number: SSA/67003/MonH-2020-240997(v1)
Monash Health Reference: RES-20-0000-860X
Effective start/end date26/11/2025/11/25


  • clinical trial
  • treatment efficacy
  • treatment safety
  • colorectal cancer
  • colorectal cancer treatment